Clinical trial
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic…
NCT00439777 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00439777 |
|---|---|
| Title | Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study |
| Official title | Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism |
| Lead sponsor | Bayer, Industry |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Embolism |
| Intervention type | Drug |
| Interventions | Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA |
| Enrollment | 4,833 |
| Start date | Mar 1, 2007 |
| Primary completion | Sep 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Feb 26, 2007 |
| Last update posted | Feb 27, 2014 |
| Countries | Andorra, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, Estonia, Finland, France and 27 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: